Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tallman, M. S.
Right arrow Articles by Rowe, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tallman, M. S.
Right arrow Articles by Rowe, J. M.
Related Collections
Right arrow Perspectives
Right arrow Clinical Trials and Observations
Right arrow Neoplasia
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 February 2002, Vol. 99, No. 3, pp. 759-767

PERSPECTIVE

Acute promyelocytic leukemia: evolving therapeutic strategies

Martin S. Tallman, Chadi Nabhan, James H. Feusner, and Jacob M. Rowe

From the Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL; Children's Hospital of Oakland, CA; and the Department of Hematology and Bone Marrow Transplantation, Technion Israel Institute of Technology, Rambam Medical Center, Haifa, Israel.

Acute promyelocytic leukemia (APL) is now the most curable subtype of acute myeloid leukemia in adults. All-trans retinoic acid (ATRA), which induces differentiation of the leukemic cells into mature granulocytes, represents the important advance. The incorporation of ATRA in induction results in a high complete remission rate, leads to rapid resolution of the characteristic life-threatening coagulopathy, and, most importantly, decreases the relapse rate compared with treatment with chemotherapy alone. However, ATRA is associated with unique toxicities not observed with conventional cytotoxic chemotherapy. A number of clinical trials have been performed to define the optimal role of ATRA in the treatment of patients. The therapeutic strategies have rapidly evolved as a result of both single institution and large cooperative group trials. Arsenic trioxide and stem cell transplantation are effective treatments for patients with APL who relapse after or are refractory to ATRA-based therapy. As experience with ATRA and arsenic trioxide in patients with APL accumulates, a number of important questions arise that need to be addressed.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Dolniak, E. Katsoulidis, N. Carayol, J. K. Altman, A. J. Redig, M. S. Tallman, T. Ueda, R. Watanabe-Fukunaga, R. Fukunaga, and L. C. Platanias
Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2
J. Biol. Chem., May 2, 2008; 283(18): 12034 - 12042.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. de la Serna, P. Montesinos, E. Vellenga, C. Rayon, R. Parody, A. Leon, J. Esteve, J. M. Bergua, G. Milone, G. Deben, et al.
Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin
Blood, April 1, 2008; 111(7): 3395 - 3402.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. K. Altman, P. Yoon, E. Katsoulidis, B. Kroczynska, A. Sassano, A. J. Redig, H. Glaser, A. Jordan, M. S. Tallman, N. Hay, et al.
Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses
J. Biol. Chem., January 25, 2008; 283(4): 1992 - 2001.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
G. J.L. Kaspers and C. M. Zwaan
Pediatric acute myeloid leukemia: towards high-quality cure of all patients
Haematologica, November 1, 2007; 92(11): 1519 - 1532.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Parekh, J. M. Polo, R. Shaknovich, P. Juszczynski, P. Lev, S. M. Ranuncolo, Y. Yin, U. Klein, G. Cattoretti, R. D. Favera, et al.
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms
Blood, September 15, 2007; 110(6): 2067 - 2074.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Asou, Y. Kishimoto, H. Kiyoi, M. Okada, Y. Kawai, M. Tsuzuki, K. Horikawa, M. Matsuda, K. Shinagawa, T. Kobayashi, et al.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
Blood, July 1, 2007; 110(1): 59 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, and L. C. Platanias
Suppressive Effects of Statins on Acute Promyelocytic Leukemia Cells
Cancer Res., May 1, 2007; 67(9): 4524 - 4532.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Lo-Coco, E. Ammatuna, and M. A. Sanz
Current treatment of acute promyelocytic leukemia
Haematologica, March 1, 2007; 92(3): 289 - 291.
[Full Text] [PDF]

Home page
 haematolHome page
X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, and M. Ruthardt
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells
Haematologica, March 1, 2007; 92(3): 323 - 331.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Chen, R. Chan, S. Waxman, and Y. Jing
Buthionine Sulfoximine Enhancement of Arsenic Trioxide-Induced Apoptosis in Leukemia and Lymphoma Cells Is Mediated via Activation of c-Jun NH2-Terminal Kinase and Up-regulation of Death Receptors
Cancer Res., December 1, 2006; 66(23): 11416 - 11423.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Yoon, N. Giafis, J. Smith, H. Mears, E. Katsoulidis, A. Sassano, J. Altman, A. J. Redig, M. S. Tallman, and L. C. Platanias
Activation of mammalian target of rapamycin and the p70 S6 kinase by arsenic trioxide in BCR-ABL-expressing cells.
Mol. Cancer Ther., November 1, 2006; 5(11): 2815 - 2823.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
J. P. CAPLAN
All-Trans Retinoic Acid (ATRA) Syndrome Can Mimic Panic Disorder
Psychosomatics, October 1, 2006; 47(5): 450 - 451.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
G. Cimino, F. Lo-Coco, S. Fenu, L. Travaglini, E. Finolezzi, M. Mancini, M. Nanni, A. Careddu, F. Fazi, F. Padula, et al.
Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia.
Cancer Res., September 1, 2006; 66(17): 8903 - 8911.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
P. Kannan-Thulasiraman, E. Katsoulidis, M. S. Tallman, J. S. C. Arthur, and L. C. Platanias
Activation of the Mitogen- and Stress-activated Kinase 1 by Arsenic Trioxide
J. Biol. Chem., August 11, 2006; 281(32): 22446 - 22452.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Giafis, E. Katsoulidis, A. Sassano, M. S. Tallman, L. S. Higgins, A. R. Nebreda, R. J. Davis, and L. C. Platanias
Role of the p38 Mitogen-Activated Protein Kinase Pathway in the Generation of Arsenic Trioxide-Dependent Cellular Responses.
Cancer Res., July 1, 2006; 66(13): 6763 - 6771.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. W. Milligan, K. Wheatley, T. Littlewood, J. I. O. Craig, A. K. Burnett, and for the NCRI Haematological Oncology Clinical Stud
Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial
Blood, June 15, 2006; 107(12): 4614 - 4622.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, A. Costanzo, L. Salvatore, N. Noguera, L. Mazzera, A. Tabilio, F. Lo-Coco, M. Levrero, and A. Bonati
MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis
Blood, June 1, 2006; 107(11): 4549 - 4553.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Ghavamzadeh, K. Alimoghaddam, S. H. Ghaffari, S. Rostami, M. Jahani, R. Hosseini, A. Mossavi, E. Baybordi, A. Khodabadeh, M. Iravani, et al.
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
Ann. Onc., January 1, 2006; 17(1): 131 - 134.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
M. A. Sanz
Treatment of Acute Promyelocytic Leukemia
Hematology, January 1, 2006; 2006(1): 147 - 155.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. Lo-Coco and E. Ammatuna
The Biology of Acute Promyelocytic Leukemia and Its Impact on Diagnosis and Treatment
Hematology, January 1, 2006; 2006(1): 156 - 161.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Sanz, M. S. Tallman, and F. Lo-Coco
Practice Points, Consensus, and Controversial Issues in the Management of Patients with Newly Diagnosed Acute Promyelocytic Leukemia
Oncologist, November 1, 2005; 10(10): 806 - 814.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Ortega, L. Madero, G. Martin, A. Verdeguer, P. Garcia, R. Parody, J. Fuster, A. Molines, A. Novo, G. Deben, et al.
Treatment With All-Trans Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group
J. Clin. Oncol., October 20, 2005; 23(30): 7632 - 7640.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Hampson, H. Chahal, F. Khanim, R. Hayden, A. Mulder, L. K. Assi, C. M. Bunce, and J. M. Lord
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC
Blood, August 15, 2005; 106(4): 1362 - 1368.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. M. Testi, A. Biondi, F. L. Coco, M. L. Moleti, F. Giona, M. Vignetti, G. Menna, F. Locatelli, A. Pession, E. Barisone, et al.
GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children
Blood, July 15, 2005; 106(2): 447 - 453.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Sanz, M. S. Tallman, and F. Lo-Coco
Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia
Blood, April 15, 2005; 105(8): 3019 - 3025.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Douer and M. S. Tallman
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
J. Clin. Oncol., April 1, 2005; 23(10): 2396 - 2410.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Rotem, A. Heyfets, O. Fingrut, D. Blickstein, M. Shaklai, and E. Flescher
Jasmonates: Novel Anticancer Agents Acting Directly and Selectively on Human Cancer Cell Mitochondria
Cancer Res., March 1, 2005; 65(5): 1984 - 1993.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Lal, Y. Li, J. Smith, A. Sassano, S. Uddin, S. Parmar, M. S. Tallman, S. Minucci, N. Hay, and L. C. Platanias
Activation of the p70 S6 kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells
Blood, February 15, 2005; 105(4): 1669 - 1677.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. de Botton, A. Fawaz, S. Chevret, H. Dombret, X. Thomas, M. Sanz, A. Guerci, J. San Miguel, J. de la Serna, A.M. Stoppa, et al.
Autologous and Allogeneic Stem-Cell Transplantation As Salvage Treatment of Acute Promyelocytic Leukemia Initially Treated With All-Trans-Retinoic Acid: A Retrospective Analysis of the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol., January 1, 2005; 23(1): 120 - 126.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Rigas and K. H. Dragnev
Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene
Oncologist, January 1, 2005; 10(1): 22 - 33.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gettinger, I. Shapira, N. Scheinfeld, and M. Grossbard
Complications of Therapy in Cancer Patients: CASE 2. Scrotal Ulceration During All-Trans-Retinoic Acid Therapy for Acute Promyelocytic Leukemia
J. Clin. Oncol., November 15, 2004; 22(22): 4648 - 4649.
[Full Text] [PDF]

Home page
 BloodHome page
F. Lo-Coco, G. Cimino, M. Breccia, N. I. Noguera, D. Diverio, E. Finolezzi, E. M. Pogliani, E. Di Bona, C. Micalizzi, M. Kropp, et al.
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia
Blood, October 1, 2004; 104(7): 1995 - 1999.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
M. Battistella, L. D Burry, and J. T Seki
Retinoic acid syndrome after one dose of all-transretinoic acid
Journal of Oncology Pharmacy Practice, September 1, 2004; 10(3): 149 - 154.
[Abstract] [PDF]

Home page
 BloodHome page
M. Levis, R. Pham, B. D. Smith, and D. Small
In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
Blood, August 15, 2004; 104(4): 1145 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Lunghi, A. Costanzo, M. Levrero, and A. Bonati
Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells
Blood, July 15, 2004; 104(2): 519 - 525.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. A. Sanz, G. Martin, M. Gonzalez, A. Leon, C. Rayon, C. Rivas, D. Colomer, E. Amutio, F. J. Capote, G. A. Milone, et al.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group
Blood, February 15, 2004; 103(4): 1237 - 1243.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
D. G. Gilliland, C. T. Jordan, and C. A. Felix
The Molecular Basis of Leukemia
Hematology, January 1, 2004; 2004(1): 80 - 97.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
R. M. Stone, M. R. O'Donnell, and M. A. Sekeres
Acute Myeloid Leukemia
Hematology, January 1, 2004; 2004(1): 98 - 117.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Schnittger, M. Weisser, C. Schoch, W. Hiddemann, T. Haferlach, and W. Kern
New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts
Blood, October 15, 2003; 102(8): 2746 - 2755.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Kambhampati, Y. Li, A. Verma, A. Sassano, B. Majchrzak, D. K. Deb, S. Parmar, N. Giafis, D. V. Kalvakolanu, A. Rahman, et al.
Activation of Protein Kinase C{delta} by All-trans-retinoic Acid
J. Biol. Chem., August 29, 2003; 278(35): 32544 - 32551.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
W.-Y. Au, C. R. Kumana, M. Kou, R. Mak, G. C. F. Chan, C.-W. Lam, and Y.-L. Kwong
Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia
Blood, July 1, 2003; 102(1): 407 - 408.
[Full Text] [PDF]

Home page
 BloodHome page
L. C. Platanias
Map kinase signaling pathways and hematologic malignancies
Blood, June 15, 2003; 101(12): 4667 - 4679.
[Abstract] [Full Text] [PDF]